Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 203

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection

Open access
Osinusi, Anu, Townsend, Kerry, Kohli, Anita, Nelson, Amy, Seamon, Cassie, Meissner, Eric G., Bon, Dimitra, Silk, Rachel, Gross, Chloe, Price, Angie, Sajadi, Mohammad, Sidharthan, Sreetha, Sims, Zayani, Herrmann, Eva, Hogan, John, Teferi, Gebeyehu, Talwani, Rohit, Proschan, Michael, Jenkins, Veronica, Kleiner, David E., Wood, Brad J., Subramanian, G. Mani, Pang, Phillip S., McHutchison, John G., Polis, Michael A., Fauci, Anthony S., Masur, Henry, Kottilil, Shyam · 2015 · JAMA

Abstract

IMPORTANCE: There is an unmet need for interferon- and ribavirin-free treatment for chronic hepatitis C virus (HCV) infection in patients co-infected with human immunodeficiency virus (HIV). OBJECTIVE: To evaluate the rates of sustained virologic response (SVR) and adverse events in previously untreated patients with HCV genotype 1 and HIV co-infection following a 12-week treatment of the fixed-dose combination of ledipasvir and sofosbuvir. DESIGN, SETTING, AND PARTICIPANTS: Open-label, single-center, phase 2b pilot study of previously untreated, noncirrhotic patients with HCV genotype 1 and HIV co-infection conducted at the Clinical Research Center of the National Institutes of Health, Bethesda, Maryland, from June 2013 to September 2014. Patients included those receiving antiretroviral therapy with HIV RNA values of 50 copies/mL or fewer and a CD4 T-lymphocyte count of 100 cells/mL or greater or patients with untreated HIV infection with a CD4 T-lymphocyte count of 500 cells/mL or greater. Serial measurements of safety parameters, virologic and host immune correlates, and adherence were performed. INTERVENTIONS: Fifty patients with HCV genotype 1 never before treated for HCV were prescribed a fixed-dose combination of ledipasvir (90 mg) and sofosbuvir (400 mg) once daily for 12 weeks. MAIN OUTCOMES AND MEASURES: The primary study outcome was the proportion of patients with sustained viral response (plasma HCV RNA level <12 IU/mL) 12 weeks after end of treatment. RESULTS: Forty-nine of 50 participants (98% [95% CI, 89% to 100%]) achieved SVR 12 weeks after end of treatment, whereas 1 patient experienced relapse at week 4 following treatment. In the patient with relapse, deep sequencing revealed a resistance associated mutation in the NS5A region conferring resistance to NS5A inhibitors, such as ledipasvir. The most common adverse events were nasal congestion (16% of patients) and myalgia (14%). There were no discontinuations or serious adverse events attributable to study drug. CONCLUSIONS AND RELEVANCE: In this open-label, uncontrolled, pilot study enrolling patients co-infected with HCV genotype 1 and HIV, administration of an oral combination of ledipasvir and sofosbuvir for 12 weeks was associated with high rates of SVR after treatment completion. Larger studies that also include patients with cirrhosis and lower CD4 T-cell counts are required to understand if the results of this study generalize to all patients co-infected with HCV and HIV. TRIAL REGISTRATION: clinicaltrials.gov Identifier:NCT01878799.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2015.1373

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 203

Metadata

Authors
Osinusi, A., Townsend, K., Kohli, A., Nelson, A., Seamon, C., Meissner, E. G., Bon, D., Silk, R., Gross, C., Price, A., Sajadi, M., Sidharthan, S., Sims, Z., Herrmann, E., Hogan, J., Teferi, G., Talwani, R., Proschan, M., Jenkins, V., Kleiner, D. E., Wood, B. J., Subramanian, G. M., Pang, P. S., McHutchison, J. G., Polis, M. A., Fauci, A. S., Masur, H., & Kottilil, S.
Venue
JAMA
Published
2015-03-24
Volume
313
Issue
12
Pages
1232
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2030470608
Cited by
203
References
1
FWCI
26.78
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection. https://app.cochat.ai/papers/10.1001/jama.2015.1373
The paper
Osinusi, A., Townsend, K., Kohli, A., Nelson, A., Seamon, C., Meissner, E. G., Bon, D., Silk, R., Gross, C., Price, A., Sajadi, M., Sidharthan, S., Sims, Z., Herrmann, E., Hogan, J., Teferi, G., Talwani, R., Proschan, M., Jenkins, V., . . . Kottilil, S. (2015). Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection. JAMA. https://doi.org/10.1001/jama.2015.1373

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.